☰

Daniel L. Gillen, Ph.D. - Publications

Affiliations: 
2003 University of Washington, Seattle, Seattle, WA 
Area:
Statistics
Tree Info Similar researchers PubMed Report error

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Grill JD, Nuño MM, Gillen DL. Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials? Alzheimer Disease and Associated Disorders. PMID 30958413 DOI: 10.1097/Wad.0000000000000303  0.31
2019 Soohoo M, Moradi H, Obi Y, Rhee CM, Gosmanova EO, Molnar MZ, Kashyap ML, Gillen DL, Kovesdy CP, Kalantar-Zadeh K, Streja E. Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes. Journal of the American Heart Association. 8: e011869. PMID 30885048 DOI: 10.1161/Jaha.118.011869  0.34
2019 Ko GJ, Obi Y, Chang TI, Soohoo M, Eriguchi R, Choi SJ, Gillen DL, Kovesdy CP, Streja E, Kalantar-Zadeh K, Rhee CM. Factors Associated With Withdrawal From Dialysis Therapy in Incident Hemodialysis Patients Aged 80 Years or Older. Journal of the American Medical Directors Association. PMID 30692035 DOI: 10.1016/J.Jamda.2018.11.030  0.323
2018 Grill JD, Hoang D, Gillen DL, Cox CG, Gombosev A, Klein K, O'Leary S, Witbracht M, Pierce A. Constructing a Local Potential Participant Registry to Improve Alzheimer's Disease Clinical Research Recruitment. Journal of Alzheimer's Disease : Jad. PMID 29710723 DOI: 10.3233/Jad-180069  0.312
2017 Nguyen VQ, Gillen DL. Censoring-robust estimation in observational survival studies: Assessing the relative effectiveness of vascular access type on patency among end-stage renal disease patients. Statistics in Biosciences. 9: 406-430. PMID 32190128 DOI: 10.1007/S12561-016-9162-Z  0.343
2017 Nuño MM, Gillen DL, Dosanjh KK, Brook J, Elashoff D, Ringman JM, Grill JD. Attitudes toward clinical trials across the Alzheimer's disease spectrum. Alzheimer's Research & Therapy. 9: 81. PMID 28978335 DOI: 10.1186/S13195-017-0311-5  0.302
2017 Obi Y, Kalantar-Zadeh K, Streja E, Rhee CM, Reddy UG, Soohoo M, Wang Y, Ravel V, You AS, Jing J, Sim JJ, Nguyen DV, Gillen DL, Saran R, Robinson B, et al. Seasonal variations in transition, mortality and kidney transplantation among patients with end-stage renal disease in the USA. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. PMID 28201764 DOI: 10.1093/Ndt/Gfw379  0.312
2017 Kalantar-Zadeh K, Kovesdy CP, Streja E, Rhee CM, Soohoo M, Chen JL, Molnar MZ, Obi Y, Gillen D, Nguyen DV, Norris KC, Sim JJ, Jacobsen SS. Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced chronic kidney disease. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. PMID 28201698 DOI: 10.1093/Ndt/Gfw357  0.307
2017 Nuño MM, Gillen DL. Alternative Sampling Designs for Time-to-Event Data With Applications to Biomarker Discovery in Alzheimer's Disease Handbook of Statistics. 36: 105-166. DOI: 10.1016/Bs.Host.2017.08.001  0.303
2014 Lertdumrongluk P, Streja E, Rhee CM, Park J, Arah OA, Brunelli SM, Nissenson AR, Gillen D, Kalantar-Zadeh K. Dose of hemodialysis and survival: a marginal structural model analysis. American Journal of Nephrology. 39: 383-91. PMID 24776927 DOI: 10.1159/000362285  0.306
2013 Brummel SS, Gillen DL. On the Use of Local Assessments for Monitoring Centrally Reviewed Endpoints with Missing Data in Clinical Trials. Open Journal of Statistics. 3: 41-54. PMID 25540717 DOI: 10.4236/Ojs.2013.34A005  0.304
2012 Nguyen VQ, Gillen DL. Robust inference in discrete hazard models for randomized clinical trials. Lifetime Data Analysis. 18: 446-69. PMID 22810273 DOI: 10.1007/S10985-012-9224-6  0.305
2009 Gillen DL. A random walk approach for quantifying uncertainty in group sequential survival trials Computational Statistics and Data Analysis. 53: 609-620. DOI: 10.1016/J.Csda.2008.08.018  0.322
2008 Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, ... ... Gillen DL, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prevention Research (Philadelphia, Pa.). 1: 32-8. PMID 18841250 DOI: 10.1158/1940-6207.Capr-08-0042  0.3
2008 Mittalhenkle A, Stehman-Breen CO, Shlipak MG, Fried LF, Katz R, Young BA, Seliger S, Gillen D, Newman AB, Psaty BM, Siscovick D. Cardiovascular risk factors and incident acute renal failure in older adults: The cardiovascular health study Clinical Journal of the American Society of Nephrology. 3: 450-456. PMID 18256380 DOI: 10.2215/Cjn.02610607  0.307
2008 Haneuse SJ, Rudser KD, Gillen DL. The separation of timescales in Bayesian survival modeling of the time-varying effect of a time-dependent exposure. Biostatistics (Oxford, England). 9: 400-10. PMID 18025072 DOI: 10.1093/Biostatistics/Kxm038  0.537
2008 Schildcrout JS, Jenkins CA, Ostroff JH, Gillen DL, Harrell FE, Trost DC. Analysis of longitudinal laboratory data in the presence of common selection mechanisms: a view toward greater emphasis on pre-marketing pharmaceutical safety. Statistics in Medicine. 27: 2248-66. PMID 17929332 DOI: 10.1002/Sim.3071  0.31
2007 Emerson SS, Kittelson JM, Gillen DL. Frequentist evaluation of group sequential clinical trial designs. Statistics in Medicine. 26: 5047-80. PMID 17573678 DOI: 10.1002/Sim.2901  0.582
2007 Stankus N, Hammes M, Gillen D, Worcester E. African American ESRD patients have a high pre-dialysis prevalence of kidney stones compared to NHANES III. Urological Research. 35: 83-7. PMID 17310350 DOI: 10.1007/S00240-007-0079-3  0.313
2007 Emerson SS, Kittelson JM, Gillen DL. Bayesian evaluation of group sequential clinical trial designs. Statistics in Medicine. 26: 1431-49. PMID 17066402 DOI: 10.1002/Sim.2640  0.58
2007 Gillen DL, Emerson SS. Nontransitivity in a class of weighted logrank statistics under nonproportional hazards Statistics and Probability Letters. 77: 123-130. DOI: 10.1016/J.Spl.2006.06.001  0.573
2006 Smith JM, Rudser K, Gillen D, Kestenbaum B, Seliger S, Weiss N, McDonald RA, Davis CL, Stehmen-Breen C. Risk of lymphoma after renal transplantation varies with time: An analysis of the United States Renal Data System Transplantation. 81: 175-180. PMID 16436959 DOI: 10.1097/01.Tp.0000188687.18972.A8  0.544
2005 Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, Jenny NS, Stehman-Breen C, Gillen D, Bleyer AJ, Hirsch C, Siscovick D, Newman AB. Kidney function as a predictor of noncardiovascular mortality. Journal of the American Society of Nephrology : Jasn. 16: 3728-35. PMID 16251239 DOI: 10.1681/Asn.2005040384  0.304
2005 Seliger SL, Longstreth WT, Katz R, Manolio T, Fried LF, Shlipak M, Stehman-Breen CO, Newman A, Sarnak M, Gillen DL, Bleyer A, Siscovick DS. Cystatin C and subclinical brain infarction. Journal of the American Society of Nephrology : Jasn. 16: 3721-7. PMID 16236809 DOI: 10.1681/Asn.2005010006  0.317
2005 Gillen DL, Emerson SS. A note on P-values under group sequential testing and nonproportional hazards. Biometrics. 61: 546-51. PMID 16011703 DOI: 10.1111/J.1541-0420.2005.040342.X  0.57
2005 Gillen DL, Emerson SS. Information Growth in a Family of Weighted Logrank Statistics Under Repeated Analyses Sequential Analysis. 24: 1-22. DOI: 10.1081/Sqa-200046825  0.593
2004 Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C. Survival following parathyroidectomy among United States dialysis patients. Kidney International. 66: 2010-6. PMID 15496173 DOI: 10.1111/J.1523-1755.2004.00972.X  0.316
2004 Seliger SL, Siscovick DS, Stehman-Breen CO, Gillen DL, Fitzpatrick A, Bleyer A, Kuller LH. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. Journal of the American Society of Nephrology : Jasn. 15: 1904-11. PMID 15213280 DOI: 10.1097/01.Asn.0000131529.60019.Fa  0.315
2003 Wasse H, Gillen DL, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, Stehman-Breen CO. Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney International. 64: 1455-61. PMID 12969166 DOI: 10.1046/J.1523-1755.2003.00225.X  0.32
2002 Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, Kestenbaum BR, Stehman-Breen C. Risk of hip fracture among dialysis and renal transplant recipients. Jama. 288: 3014-8. PMID 12479766 DOI: 10.1001/Jama.288.23.3014  0.581
2002 Fung F, Sherrard DJ, Gillen DL, Wong C, Kestenbaum B, Seliger S, Ball A, Stehman-Breen C. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 40: 307-14. PMID 12148103 DOI: 10.1053/Ajkd.2002.34509  0.314
2002 Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney International. 61: 2157-64. PMID 12028456 DOI: 10.1046/J.1523-1755.2002.00355.X  0.311
2002 Wong CS, Hingorani S, Gillen DL, Sherrard DJ, Watkins SL, Brandt JR, Ball A, Stehman-Breen CO. Hypoalbuminemia and risk of death in pediatric patients with end-stage renal disease. Kidney International. 61: 630-7. PMID 11849406 DOI: 10.1046/J.1523-1755.2002.00169.X  0.319
2002 Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney International. 61: 297-304. PMID 11786112 DOI: 10.1046/J.1523-1755.2002.00109.X  0.31
2001 Gibson KD, Gillen DL, Caps MT, Kohler TR, Sherrard DJ, Stehman-Breen CO. Vascular access survival and incidence of revisions: A comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study Journal of Vascular Surgery. 34: 694-700. PMID 11668326 DOI: 10.1067/Mva.2001.117890  0.323
2001 Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO. Risk factors and mortality associated with calciphylaxis in end-stage renal disease Kidney International. 60: 324-332. PMID 11422768 DOI: 10.1046/J.1523-1755.2001.00803.X  0.332
2000 Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, Ball A, Weiss NS. Risk factors for hip fracture among patients with end-stage renal disease Kidney International. 58: 2200-2205. PMID 11044242 DOI: 10.1111/J.1523-1755.2000.00394.X  0.302
2000 Wong CS, Gipson DS, Gillen DL, Emerson S, Koepsell T, Sherrard DJ, Watkins SL, Stehman-Breen C. Anthropometric measures and risk of death in children with end-stage renal disease American Journal of Kidney Diseases. 36: 811-819. PMID 11007685 DOI: 10.1053/Ajkd.2000.17674  0.33
1999 Stehman-Breen CO, Gillen D, Gipson D. Prescription of hormone replacement therapy in postmenopausal women with renal failure. Kidney International. 56: 2243-2247. PMID 10594801 DOI: 10.1046/J.1523-1755.1999.00793.X  0.304
Show low-probability matches.